Announcement: Tailored drug combinations show promise against treatment-resistant melanoma in preclinical study

ბოლო განახლება: 26/08/2026 05:30

ავტორი:

0 Min Read

Researchers at MD Anderson Cancer Center have developed a strategy to match drug combinations to tumor biomarkers in treatment-resistant melanoma, showing promise in preclinical models. This precision oncology approach may improve outcomes for patients who fail standard therapies. — Photo by Tara Winstead on Pexels (Pexels License)

1 min read|52 words

Researchers at MD Anderson Cancer Center have identified a way to match drug combinations to tumor biomarkers in treatment-resistant melanoma. The preclinical strategy tailors therapy to individual tumor biology, potentially improving outcomes for patients who fail standard treatments. Read the full analysis on GMJ News.

Read the full article on GMJ Newsroom →

Was this article helpful?

GMJ Brief · Announcement

📰 Read the full article: Tailored drug combinations show promise against treatment-resistant melanoma in preclinical study →

Share This Article

ავტორი:Prof. Giorgi Pkhakadze

Follow:

Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Announcement: Tailored drug combinations show promise against treatment-resistant melanoma in preclinical study

Submit Your Paper →

Ethiopia Study Reveals Stakeholder Concerns Over Novel Malaria Treatments

Sitafloxacin monotherapy matches doxycycline-rifampicin for brucellosis treatment in landmark trial

Ultra-processed foods linked to higher kidney cancer risk in large US study

Submit Your Paper to GMJ

Company

You Might Also Like